×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Skin Cancer

Felicia Mitchell
After radiation, as the skin heals, a compassionate dermatologist can help us to monitor any lingering side-effects.
Jason M. Broderick
The combination therapy of Tafinlar (dabrafenib) and Mekinist (trametinib) was granted Food and Drug Administration (FDA) approval for the treatment of patients with BRAF V600E– or V600K–positive stage 3 melanoma following complete resection.
Jason M. Broderick
The Food and Drug Administration (FDA) granted a priority review to a biologics license application (BLA) for an immunotherapy agent – cemiplimab – to be used to treat metastatic cutaneous squamous cell carcinoma (a type of skin cancer; CSCC) or patients with locally advanced CSCC who are not eligible for surgery.
Tamera Anderson-Hanna
May is skin cancer awareness month, and a good reminder to schedule an appointment with your dermatologist.
Katie Kosko
Age should not limit which patients with metastatic melanoma receive immunotherapy.
Brielle Urciuoli
For patients with melanoma, administration of a PD-1 checkpoint blockade therapy in the neoadjuvant setting – meaning it was given before the main treatment – could result in improved outcomes and better insight to patient responses. 
Brielle Urciuoli
Tests like these are growing increasingly important, as TOO results lead to treatment changes about 65 percent of the time and a site treatment change about 35 percent of the time, according to Cancer Genetics.
Barbara Tako
"I have grown as a person since becoming a cancer survivor," says breast cancer and melanoma survivor Barbara Tako.
Kristie L. Kahl
After a recent FDA approval for an additional dosing schedule option for Opdivo, patients must be educated on the potential side effects that may occur between prolonged visits.
Brielle Urciuoli
A recent study conducted at UCLA showed that nearly all patients with uveal melanoma reported having unmet psychologic and informational needs, especially in the few months following their diagnosis.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable